Evaluating the efficacy of intralesional verapamil over intralesional triamcinolone in management of keloid: an evidence based case report

Bertha Kawilarang


Author present a case of 22-year-old female with keloid due to previous trauma three years prior. Keloids are excessive fibroblast growth present in pathological scars. Therapy for keloids still remain a challenge requiring an effective intervention. While the first line has always been the use of intralesional triamcinolone, recently intralesional verapamil has also been known to reduce growth of keloids. Aim of the study was to evaluate the efficacy of both of these drug options. Literature searching was performed from three databases namely PubMed, Cochrane library and Science Direct. Findings were systematically narrowed down through inclusion and exclusion criteria into four relevant randomized controlled trials. Selected studies were critically appraised for its validity, importance, and applicability using tools from Oxford Center of Evidence-Based Medicine. Both intralesional triamcinolone and verapamil show their own benefit and risk. Triamcinolone is more effective in reducing keloid with faster improvement as seen in scar height reduction, vascularity, pigmentation and pliability. However, verapamil has fewer side effects which serve as a safer treatment option. More clinical trials in the future may be needed to obtain more conclusive result.


Efficacy, Evidence-based, Intralesional triamcinolone, Keloid, Verapamil

Full Text:



Tsai CH, Ogawa R. Keloid research: current status and future directions. Scars, Burns Healing. 2019 Aug;5:1-8.

Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. Int J Mol Sci. 2017 Mar;18(3):606.

Ningsih SS, Sari DH, Antarianto RD, Hardiany NS, Sadikin M, Wanandi SI, et al. Expressions of stemness markers in keloid tissue. Med J Indonesia. 2018 Oct 12;27(3):145-9.

Mufti ST, Moshref SS. Keloid and hypertrophic scars: comparative histopathological and immunohistochemical study. J King Abdulaziz Uni: Med Sci. 2010 Jun;98(279):1-39.

Halim AS, Emami A, Salahshourifar I, Kannan TP. Keloid scarring: understanding the genetic basis, advances, and prospects. Arch Plastic Surg. 2012 May;39(3):184.

Ud-Din S, Bayat A. New insights on keloids, hypertrophic scars, and striae. Dermatol Clin. 2014 Apr 1;32(2):193-209.

Ogawa R, Akaishi S. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis–keloids and hypertrophic scars may be vascular disorders. Med Hypo. 2016 Nov 1;96:51-60.

Arno AI, Gauglitz GG, Barret JP, Jeschke MG. Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. Burns. 2014 Nov 1;40(7):1255-66.

Ledon JA, Savas J, Franca K, Chacon A, Nouri K. Intralesional treatment for keloids and hypertrophic scars: a review. Dermatol Surg. 2013 Dec 1;39(12):1745-57.

Ogawa R, Akaishi S, Kuribayashi S, Miyashita T. Keloids and hypertrophic scars can now be cured completely: recent progress in our understanding of the pathogenesis of keloids and hypertrophic scars and the most promising current therapeutic strategy. J Nippon Med School. 2016 Apr 15;83(2):46-53.

Wong TS, Li JZ, Chen S, Chan JY, Gao W. The efficacy of triamcinolone acetonide in keloid treatment: a systematic review and meta-analysis. Frontiers Med. 2016 Dec 27;3:71.

Li Z, Jin Z. Comparative effect and safety of verapamil in keloid and hypertrophic scar treatment: a meta-analysis. Thera Clin Risk Manag. 2016;12:1635.

Saki N, Mokhtari R, Nozari F. Comparing the efficacy of intralesional triamcinolone acetonide with verapamil in treatment of keloids: A randomized controlled trial. Dermatol Pract Conceptual. 2019 Jan;9(1):4.

Zamanian A, Nokandeh M, Behrangi E, Fazel Z, Azizian Z. Comparing Efficacy and Tolerability of Triamcinolone and Verapamil in Treatment of Hypertrophic Scars and Keloids. J Ski Stem Cell. 2017;4(3):1-4.

Abedini R, Sasani P, Mahmoudi HR, Nasimi M, Teymourpour A, Shadlou Z. Comparison of intralesional verapamil versus intralesional corticosteroids in treatment of keloids and hypertrophic scars: A randomized controlled trial. Burns. 2018 Sep 1;44(6):1482-8.

Ahuja RB, Chatterjee P. Comparative efficacy of intralesional verapamil hydrochloride and triamcinolone acetonide in hypertrophic scars and keloids. Burns. 2014 Jun 1;40(4):583-8.

Jfri A, Rajeh N, Karkashan E. A case of multiple spontaneous keloid scars. Case Reports Dermatol. 2015;7(2):156-60.

Yoo MG, Kim IH. Keloids and hypertrophic scars: characteristic vascular structures visualized by using dermoscopy. Annal Dermatol. 2014 Oct 1;26(5):603-9.

Chike-Obi C, Cole P, Brissett A. Keloids: pathogenesis, clinical features, and management. Semin Plast Surg. 2009;23(3):178-84.

Coppola MM, Salzillo R, Segreto F, Persichetti P. Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives. Clin, Cosmetic Investig Dermatol. 2018;11:387.

Tan S, Khumalo N, Bayat A. Understanding keloid pathobiology from a quasi-neoplastic perspective: less of a scar and more of a chronic inflammatory disease with cancer-like tendencies. Frontiers Immunol. 2019;10:1810.

Gauglitz GG. Management of keloids and hypertrophic scars: current and emerging options. Clinical, Cosmetic Investig Dermatol. 2013;6:103.

Danielsen PL, Rea SM, Wood FM, Fear MW, Viola HM, Hool LC, et al. Verapamil is less effective than triamcinolone for prevention of keloid scar recurrence after excision in a randomized controlled trial. Acta Dermato-venereol. 2016 Aug 1;96(6):774-9.

Huu ND, Huu SN, Le Thi X, Van TN, Minh PP, Minh TT, et al. Successful Treatment of Intralesional Triamcilonon Acetonide Injection in Keloid Patients. Open Access Maced J Med Sci. 2019 Jan 30;7(2):275.

Sadeghinia A, Sadeghinia S. Comparison of the efficacy of intralesional triamcinolone acetonide and 5‐fluorouracil tattooing for the treatment of keloids. Dermatol Surg. 2012 Jan;38(1):104-9.

Roques C, Téot L. The use of corticosteroids to treat keloids: a review. Int J Lower Extremity Wounds. 2008 Sep;7(3):137-45.

Hunasgi S, Koneru A, Vanishree M, Shamala R. Keloid: A case report and review of pathophysiology and differences between keloid and hypertrophic scars. J Oral Maxillofac Pathol. 2013;17(1):116-20.

Boggio RF, Boggio LF, Galvão BL, Machado-Santelli GM. Topical verapamil as a scar modulator. Aesthetic Plastic Surg. 2014 Oct 1;38(5):968-75.

Jannati P, Aref S, Jannati A, Jannati F, H M. Comparison of therapeutic response of keloids to cryotherapy plus intralesional triamcinolone acetonide or verapamil hydrochloride. J Ski Stem Cell. 2015;2(1):e29284.

Shah YM, Garg AM, Paliwal G, Ansari AS, Jain C, Rastogi R. A study of verapamil in treatment of keloid. Int J Res. 2018 Apr;4(2):176.

Srivastava S, Kumari H, Singh A. Comparison of fractional CO2 Laser, Verapamil, and Triamcinolone for the treatment of Keloid. Adv Wound Care. 2019 Jan 1;8(1):7-13.

Fearmonti R, Bond J, Erdmann D, Levinson H. A review of scar scales and scar measuring devices. Eplasty. 2010;10.